/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Marc Espié

Université Paris Cité(FR)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

376

Papers

10.1K

Citations

56

h-index

120

i10-index

Marc Espié is an academic researcher from Université Paris Cité. The author has contributed to research in topics: Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research. The author has an h-index of 56, co-authored 320 publications.

ORCID: 0000-0003-2317-9659

Research Topics

Breast Cancer Treatment Studies Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Breast Lesions and Carcinomas Medical Imaging Techniques and Applications

Papers by this author

works

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

2013 · The Lancet Oncology · 337 citations

https://doi.org/10.1016/s1470-2045(13)70225-0

X. Pivot Gilles Romieu Marc Debled Jean‐Yves Pierga

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

2012 · Journal of Clinical Oncology · 161 citations

https://doi.org/10.1200/jco.2011.36.7771

José Baselga J. G. M. Segalla Henri Roché Auro del Giglio

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

2015 · The Lancet Oncology · 127 citations

https://doi.org/10.1016/s1470-2045(15)00373-3

Javier Cortés Véronique Dièras Jungsil Ro Jérôme Barrière

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

2010 · Breast Cancer Research and Treatment · 105 citations

https://doi.org/10.1007/s10549-010-0939-3

Jean‐Yves Pierga Suzette Delaloge Marc Espié Étienne Brain

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15

2013 · Breast Cancer Research · 98 citations

https://doi.org/10.1186/bcr3421

Jacqueline Lehmann‐Che Anne‐Sophie Hamy Raphaël Porcher Marc Barritault

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

2013 · British Journal of Cancer · 83 citations

https://doi.org/10.1038/bjc.2013.469

David Groheux Sylvie Giacchetti Mathieu Hatt M. Marty

Research topics

topics

Breast Cancer Treatment Studies

Cancer Treatment and Pharmacology

HER2/EGFR in Cancer Research

Breast Lesions and Carcinomas

Medical Imaging Techniques and Applications

Chat about Author

Papers

Chat

Click to start Chat